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Numerous genetic, environmental, and hormonal factors underlie the pathogenesis of •	
asthma leading to an abnormal antigen–antibody reaction inducing a vago-vagal axon 
reflex-mediated bronchoconstriction.
Asthma has a complex and largely undefined genetic background. Similar to most com-•	
plex diseases, its heterogeneous phenotype is thought to result from the interaction 
between multiple genes and environmental factors.
It has been estimated that 73% of asthma determinants are genetic. Moreover, genetic •	
variation is also thought to account for approximately 60–80% of the inter-individual 
variability in therapeutic response to medical treatments.
Epigenetics seems to explain the corticosteroid resistance in patients with COPD.•	
Over 25 genes have been hypothesized to be involved in asthma pathogenesis. However, •	
the data reported in genome-wide linkage studies, candidate gene association studies, 
and, more recently, genome-wide association studies do not support a substantial role 
of single genes in the development of asthma.
Future research should be planned to explore gene–environment and gene–gene interac-•	
tions to unravel the etiology of this complex condition.
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inTroducTion
Asthma is characterized by acute clinical symptoms such as bronchoconstriction, 
bronchial inflammation and cough due to increased smooth muscle contractility, epithe-
lial secretion, and tissue remodeling ultimately leading to airway thickening. Numerous 
genetic, environmental, and hormonal factors underlie the pathological antigen–antibody 
reaction inducing a vago-vagal axon reflex. The biochemical mechanisms involved in 
asthma exacerbations include a disequilibrium between two opposite second messenger 
systems in the airways, favoring the PLC–PKC over the cAMP cascade.
Asthma has a complex and largely undefined genetic background. Similar to most 
complex diseases, its heterogeneous phenotype is thought to result from the interaction 
between multiple genes and environmental factors. The concordance of asthma in 
monozygotic twins is 65%, significantly higher compared to 25% in dizygotic twins (1), 
thus supporting a necessary but not sufficient genetic component in the individual pre-
disposition to the disease and it has been calculated that 73% of asthma determinants 
are genetic. Moreover, genetic variation is also thought to account for approximately 
60–80% of the inter-individual variability in therapeutic response to medical treatments. 
One of the major obstacles in these studies is represented by the wide clinical variability 
of asthma in terms of severity, age of onset, confounding factors (such as tobacco 
smoke), and treatment response. Asthma is probably the most common chronic disease 
in children of developed country; then, significant effort has been invested in the search 
for its genetic predisposition factors. Unfortunately, there has been independent replica-
tion only for a few study findings, mostly due to the lack of statistical power, differences 
in study design, and demographic differences of the studied populations resulting in 
different genetic background or environmental factor exposure (2, 3). Genome-wide 
linkage studies, candidate gene association studies, and, more recently, genome-wide 
association studies (GWAS) have been used to investigate the genetic basis of asthma 
over the past decades. Several ch omosomal regions were found to be linked to asthma 
and related disorders, and a number of genes within these regions seem to be biologi-
cally relevant in the pathogenesis of the disease.
In general terms, the proteins encoded by the reported genes are mostly transcription 
factors, and cytokines or receptors involved in Th2 polarization, chemokines and chem-
okine receptors playing a role in inflammatory cell recruitment into the airways, chloride 
channels responsible for hypersecretion, proteins regulating allergic reaction through 
IgE, leukotrienes, prostaglandins, and major histocompatibility proteins or proteins 
involved in reactive oxygen species scavenging and tissue remodeling (Table 1). These 
findings will be critically discussed in the present chapter and we will illustrate the pos-
sible functional implications of the reported associations, while further details on the 
pathogenesis and treatment issues can be found in other chapters of this book.
THe cAse of AToPic dermATiTis
The first atopic manifestation is thought to be atopic dermatitis, being the skin the first 
site of sensitization, thus making dermatitis an ideal companion for asthma in this dis-
cussion. Generally, during the first years of life, a progression from atopic dermatitis to 
asthma and allergic rhinitis develops and no individual risk factor is sufficient to explain 
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Table 1  
major Genetic Associations reported in Asthma and the relative Protein function
Gene Chromosome Protein function
IFNG 12q14 Cytokine involved in Th1 response
STAT6 12q13 Transcriptional factor regulating Th2 response
IL-4R 16p12 Cytokine receptor involved in Th2 response
IL-13 5q31 Cytokine involved in Th2 response
ADAM33 20p13 A disintegrin and metalloprotease (ADAM) metal-
lopeptidase domain 33
GPRA 7p14 Neuropeptide S receptor 1
DPP10 2q14 Dipeptidyl-peptidase
PHF11 13q14 PHD finger protein 11
CD14 5q31 Myeloid cell-specific leucine-rich glycoprotein
TLR4 9q33 Protein recognizing pathogen-associated molecular 
patterns (PAMPs) that are expressed on infectious 
agents (i.e., bacterial LPS)
TLR2 4q32 Protein recognizing PAMPs that are expressed on 
infectious agents (i.e., gram-positive bacteria and 
yeast)
TLR9 3p21 Protein recognizing unmethylated CpG dinucleotides 
in bacterial DNA
CARD15 16q21 Caspase-recruitment domain containing protein 15 
(CARD15), cytosolic receptor involved in bacterial 
recognition by antigen-presenting cells
TGFB1 19q13 Cytokine involved in fibrogenesis
ADRB2 5q31 b-2-Adrenergic receptor
NOS 12q24 Nitric oxide synthase
SPINK5 5q32 Serine peptidase inhibitor, Kazal type 5
GST (T1,M1,P1) 22q11,1p13  
11q13
Glutathione S-transferases (GST)
PDE4D 5q12 Lung-expressed phosphodiesterase implicated in airway 
contractility
ORMDL3 17q21 Transmembrane protein anchored to endoplasmic 
reticulum
GSDML 17q21 Gasdermin protein regulating apoptosis in epithelial 
cells
DENND1B 1q31 Protein interacting with TNF-a receptor and expressed 
by natural killer and dendritic cells
these alterations in global atopic disease prevalence (4). Differences in the prevalence 
between urban and rural populations or farming communities have been attributed to the 
risk of atopy, including diet, hygiene, infections, allergens, and air pollution, in combina-
tion with genetic factors. Exposure to household pets, livestock, unpasteurized milk, and 
endotoxins during childhood are associated with a reduced incidence of allergic mani-
festations, although the data are inconsistently reported overall (4). Nevertheless, there 
is convincing evidence that demonstrates a clear correlation between increased microbial 
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exposure and reduced allergic sensitization. In recent studies comparing geographically 
distinct but genetically related pediatric populations in Finland and Russia, a significant, 
dose-dependent reduction in the risk of atopy associated with microbial cell content and 
prevalence of enteroviruses has been demonstrated (5–7).
The mechanisms by which allergen exposure through the epidermis could initiate 
systemic allergy and start the so-called “atopic march” (4) and predispose individuals 
to asthma have been elucidated during the past years. There is evidence implicating a 
primary inherited epithelial barrier defect resulting from filaggrin gene null mutations 
as a major predisposing factor in a subset of patients with atopic dermatitis and, second-
arily, to the development of asthma (8). Other less known epithelial defects, such as 
SPINK5, also may have a role (9). Proinflammatory factors derived from keratinocytes 
and other epithelial cells have also elicited considerable interest, including thymic stro-
mal lymphopoietin, which has been shown to stimulate mast cells to produce Th2 
cytokines (10). These data suggest potential molecular targets for preventing allergen 
sensitization associated with epithelial barrier disruption and halting the progression of 
atopic dermatitis and other atopic diseases.
Genome-Wide LinKAGe sTudies
Prior to the GWAS era, several genome-wide linkage studies or candidate gene asso-
ciation studies were performed to identify gene and chromosomal regions linked to 
asthma. Nevertheless and as previously mentioned, differences in study design, studied 
population origins, low statistical power led to various results. Genome-wide linkage 
studies reported that the regions and genes more consistently associated with asthma 
are cytokine cluster on chromosome 5q, INFG (INF-g) and STAT6 on 12q, and IL-4R 
(IL-4Ra) on 16p (3).
Serum INF-g levels have been found to be significantly lower in patients with atopic 
asthma. IFN-g plays an important anti-inflammatory role in asthma, as it suppresses 
tumor necrosis factor (TNF)-a signaling in atopic patients, and expression of IL-6, IL-8, 
and eotaxin induced by exposure to TNF-a. It also induces inflammatory genes such as 
vascular endothelial growth factor (VEGF), and the expression of IL-17 receptor (11). 
The increased acetylation of the nuclear factor kB (NF-kB) p65 subunit as a result of 
TNF-a signaling is considerably reduced by IFN-g. These findings suggest that IFN-g 
suppresses the expression of some, but not all, pro-inflammatory genes induced by 
TNF-a by interfering with the transcriptional activity of NF-kB, possibly through 
changes in acetylation levels of the key regulatory proteins. Based on this background, 
the single nucleotide polymorphism (SNPs), T–A, at the 5¢ end of the CA repeat of the 
human IFN-g gene (+874T/A) directly affects the level of IFN-g production and the 
A874 allele correlates with a low production of IFN-g (4). This polymorphism seems to 
coincide with a putative NF-kB binding site that could have functional consequences 
for the transcription of the human IFN-g gene, with the result that the polymorphism 
could directly influence the level of IFN-g production.
STAT6 is critical for Th2 cytokine signaling (12). Multiple sequence variants of the 
STAT6 gene have been identified, some of which are associated with atopic phenotypes 
in diverse populations (12). Seven dinucleotide GT repeat variants were identified in the 
noncoding exon 1 of STAT6. Case–control association analysis of 214 white British 
[AU2]
[AU3]
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
Un
co
rre
cte
d P
ro
of
The Genetic Bases of Asthma
subjects demonstrated significant association with asthma of an allele with a 13GT 
repeat sequence (GT13), whereas the GT16 allele showed an inverse association with 
asthma. Furthermore, individuals with the GT13 allele had a higher level of IgE com-
pared with individuals with the GT16 allele. Transient transfection assays of different 
alleles revealed significantly higher transcriptional activity with the GT13 allele com-
pared with the GT16 allele in in vitro cell lines. Moreover, the GT13 allele had signifi-
cantly decreased binding stability compared with the GT16 allele in a reciprocal 
competitive assay. These findings suggest that the GT repeat polymorphism of the 
STAT6 gene contributes to susceptibility to atopic asthma and total serum IgE levels, 
and that variation in the length of the GT repeat sequence influences the regulation of 
promoter activity (12).
Linkage studies followed by positional cloning have identified novel genes involved 
in asthma susceptibility including ADAM33 on chromosome 20p, GPRA on chromo-
some 7p, DPP10 on chromosome 2q, and PHF11 on chromosome 13.
ADAM33 is a member of the ADAM (a disintegrin and metalloprotease) family. 
ADAM proteins are involved in cell adhesion, cell fusion, cell signaling, and proteolysis 
(13). These proteins have the capacity to shed cytokines, growth factors, or their receptors 
from the cell surface and the remodeling of extracellular matrix components. The enzy-
matic activity of ADAM33 can be inhibited by tissue inhibitor of metalloproteinase-3 
and -4 (TIMP-3 and -4, respectively) as well as several small molecules. This suggests 
that ADAM33 is involved in pulmonary defenses and tissue remodeling. In fact, a 
crucial pathological feature of chronic respiratory diseases such as asthma is airway 
inflammation and remodeling leading to airflow obstruction. A truncated, soluble form 
of ADAM33 containing the catalytic domain caused rapid induction of endothelial cell 
differentiation in vitro and angiogenesis ex vivo and in vivo, thus suggesting its possible 
involvement even in lung vascular remodeling in COPD. Genome-wide screening 
revealed that chromosome 20p13 was significantly linked to asthma and airway hyper-
responsiveness in 460 families with asthma from the UK and the USA (14). This 
genomic region contains the gene ADAM33. Since the first report of an association 
between ADAM33 polymorphisms and asthma in two Caucasian populations from the 
UK and the USA, a number of replication studies have been published with differing 
results (14). The differences in the association results may be due to phenotypic and 
environmental heterogeneity between cohorts. Additional studies demonstrated that 
SNPs within the ADAM33 locus are associated with accelerated decline of lung function 
in the general population and in patients with asthma. The ADAM33 gene is expressed 
in airway smooth muscle cells and fibroblasts in the lung, suggesting that it is not only 
important in the development of asthma but also in disease progression, possibly through 
airway remodeling (13). These latter findings suggest a function of ADAM33 related to 
lung growth and repair in general rather than solely associated with asthma. Recent studies 
revealed that SNPs within ADAM33 confer susceptibility to COPD in the general popu-
lation and are associated with airway inflammation in COPD.
GPRA, G-protein-coupled receptor for asthma susceptibility, also known as 
G-protein-coupled receptor 154, GPR154, located on chromosome 7 was identified as 
an asthma candidate gene by positional cloning in Finnish and French Canadian popula-
tions (15). GPRA has two main isoforms with alternatively spliced 3¢ exons (371 amino 
acids for isoform A and 377 amino acids for isoform B) and distinct tissue distribution 
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patterns. Expression patterns of the GPRA-B pulmonary isoform are different between 
asthma patients and healthy controls (15). Moreover, levels of the GPRA-B isoform are 
increased in airway smooth muscle cells and epithelial cells in asthma patients com-
pared to healthy controls. These data suggest that GPRA plays a role in asthma patho-
genesis. GPRA single nucleotide polymorphisms (SNPs) and haplotypes have been 
associated with asthma or atopy in several studies, but not in others. In the studies in 
which associations have been found, however, the SNPs and haplotypes related to 
asthma and atopy are inconsistent across populations. Thus, the role of genetic variation 
in GPRA in asthma and atopy remains inconclusive.
cAndidATe Gene AssociATion sTudies
Over the past years, candidate gene association studies identified several candidate 
genes with a few of these results being replicated in subsequent works.
Some of the candidate genes are involved in innate immunity such as TLRs, CD14, 
CARD15. The development of allergic disease may be influenced by bacterial and viral 
infections (2). Thus, genes involved with the innate immunity response are obvious 
candidates for the understanding of the protective effects of exposure to microbial 
agents on allergy and asthma. Indeed, several SNPs in genes encoding pattern recogni-
tion receptors such as CD14 and toll-like receptors (TLR) have been associated with 
atopic sensitization and asthma. Gene–environment interactions were found between 
ten SNPs in CD14, TLR4, TLR2, and TLR9 and living in the country during childhood, 
which was presumed to represent higher exposures to various microbial agents (3). Of note, 
these observations follow the hygiene hypothesis that has been proposed for numerous 
immune-mediated conditions (3). Main effects and gene–environment interactions were 
stronger in subjects who were atopic than in those who were nonatopic. In particular, 
an association has been found between the TLR2/+596 polymorphism and asthma and 
between CD14/−260 SNP and asthma.
Since TLR2 is involved in the recognition of microbial motifs of a wide range of 
Gram-positive microorganisms, mycobacteria, and yeast, the exposure to these micro-
organisms is likely to occur more frequently in rural compared to industrialized areas. 
A lower expression of TLR2 on the surface of innate immune cells in carriers of the 
TLR2/+596C allele would be associated with a lesser protective effect of environmental 
exposures to TLR2 ligands on asthma (16, 17). On the other hand, TLR9 is a receptor 
for bacterial CpG DNA motifs and the studies investigating TLR9 SNPs in relation to 
allergy or asthma have reported inconsistent associations. However, significant gene–
gene interactions with the TLR2/+596 SNP were demonstrated, showing effects of two 
TLR9 SNPs on asthma in TLR2/+596 TT subjects (16, 17). Interestingly, TLR9 and 
TLR2 have different ligands and these observations may cumulatively reflect an interac-
tive effect of multiple microbial exposures to determine asthma onset.
Genetic variants of the caspase-recruitment domain containing protein 15 (CARD15) 
that might result in inappropriate immunomodulation are not only associated with 
autoimmune diseases (18), but also with atopic disorders. CARD15 is a cytosolic 
receptor involved in bacterial recognition by antigen-presenting cells. Subjects carrying 
the T allele at rs1077861 manifest a decreased risk of developing asthma, whereas the 
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presence of an A allele at rs3135500 is significantly associated with an increased risk 
(19). In addition, a CARD15 haplotype revealed to be protective against the develop-
ment of asthma (19).
Other candidate genes involved in inflammation include specific cytokines and 
chemokines, and also the respective signaling pathway such as mediators involved in 
IL-4/IL-13 signaling. IL-4 and IL-13 are pleiotropic, proinflammatory cytokines pro-
duced by activated T cells as part of an immune response to allergen exposure. The 
genes for IL-4 and IL-13 lie in a cytokine cluster on chromosome 5q31, a locus previ-
ously linked to several asthma phenotype. IL-4 and IL-13 are characterized by struc-
tural and functional similarities, as well as a common receptor component, IL-4Ra, 
located on chromosome 16p11. IL-4 plays important roles in T cell development, eosi-
nophilic inflammation, and IgM–IgE isotype switching in B cells. IL-13 is a Th2 
cytokine found to be overexpressed in the lungs of patients with asthma and in murine 
models of the disease (20). Studies of the 5q31 locus reported significant associations 
between genetic variants in IL-4 and IL-13 genes and asthma or asthma-related pheno-
types in some populations (20–22). It has been reported an association between the 
IL-4 C-589T allele and asthma severity in whites but not in African-Americans. 
Similarly, other nine SNPs in the IL-4 gene have been found to be significantly associ-
ated with asthma or total serum IgE in whites (21). It has also been reported an associa-
tion between asthma-related phenotypes and polymorphisms in both the IL-13 and 
IL-4Ra genes, as well as evidence of gene–gene interaction between IL-13 C-1112T 
and IL-4Ra C+22656T (S478P) SNPs as a contributor to asthma susceptibility. In 
another study, a significant gene–gene interactions has been reported between the IL-13 
R130Q and IL-4Ra Ile50Val (A+4679G) polymorphisms for asthma risk in a Chinese 
population. Moreover, a significant gene–gene interaction was found between the IL-13 
(A-646G) and IL-4Ra (A-4679G) SNPs for baseline lung function among African-
American subjects with asthma (22).
Interestingly, additional candidate genes are involved in lung function, growth, and 
development such as TGFB1, ADRB2, NOS1 and 3, and SPINK5. Polymorphisms in the 
transforming growth factor-b1 (TGF-b1) gene have been implicated in susceptibility to 
asthma, but a large number of studies have reported inconclusive results. A meta-analysis 
performed to investigate the association between polymorphisms in the TGF-b1 gene 
and asthma susceptibility suggested that the −509C/T polymorphism in the TGF-b1 
gene may be a risk factor for asthma (23). On the other hand, b-2-adrenergic receptors 
(b(2)AR) participate in the physiologic responses of the lung, including bronchodilation 
and bronchial protection, through mechanisms such as ciliary clearance, fluid accumula-
tion, and mediator release from mast cells and basophils. Thus, these receptors may also 
play an important role in the pathophysiology of asthma. The gene encoding b(2)AR, 
ADRB2, is extremely polymorphic, but it appears that, for asthma, ADRB2 polymor-
phisms are not etiologically involved (24). However, they might affect disease severity 
and clinical response to both acute and chronic administration of b(2)-agonists. Finally, 
genes involved in the response to environmental exposures to pollutants and tobacco 
have been also found to be associated with asthma such as GSTM1, GSTP1, and GSTT1. 
Oxidative stress in the lungs has been implicated in the pathogenesis of asthma. Sources 
of oxidant injury are reactive oxygen and nitrogen species generated by activated 
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 inflammatory cells and bronchial epithelial cells and inhalation of atmospheric pollutants, 
notably tobacco smoke and oxidant gases, including ozone, sulfur dioxide, and nitrogen 
oxides. These are countered by enzymatic and nonenzymatic antioxidants, including 
dietary antioxidants, such as flavanols, vitamins C and E, and glutathione, a major 
protective antioxidant in the lungs that also has a role in regulation of inflammatory 
responses. The enzyme family of glutathione-S-transferases (GST) has the general func-
tion of conjugating glutathione with electrophilic substances that are capable of generat-
ing free radicals, thus leading to detoxification of their effects. Genetic polymorphisms 
associated with reduced activity of GST are therefore of interest in the study of asthma 
susceptibility. Two common deletion polymorphisms of GSTM1 and GSTT1 genes have 
been associated with asthma in children and adults (25). The Val allele of the GSTP1 
Ile105Val polymorphism, associated with reduced glutathione activity, has been reported 
to be either protective or associated with increased risk of asthma. A recent meta-
analysis does not support a substantial role of GST genes on asthma phenotypes in either 
children or adults, although small effects cannot be excluded and it is possible that these 
genes act on airway disease through interaction with environmental exposures or other 
genes (25). Future studies on larger populations are warranted to evaluate GST genes in 
addition to other antioxidant genes or to air pollution and tobacco smoke exposures or 
the possible association of GST genes with asthma severity are needed to provide evi-
dence on gene–gene interactive effects on asthma.
One final and fascinating hint for the etiology of asthma comes from a rare condition. 
The mutation of SPINK5 causes Netherton syndrome, a rare recessive skin disease that 
is accompanied by severe atopic manifestations including atopic dermatitis, allergic 
rhinitis, high serum IgE, hypereosinophilia, and asthma. The SNP −206G>A of the 
SPINK5 promoter is significantly associated with atopy, atopic dermatitis, asthma, and 
total serum IgE (26). Moreover, the A allele at −206G>A has a significantly higher 
transcriptional activity than the G allele. Electrophoresis mobility shift assay also 
showed a significantly higher binding efficiency of nuclear protein to the A allele com-
pared with the G allele.
Genome-Wide AssociATion sTudies
GWAS involving large cohorts of patients and controls have recently been performed 
in a growing number of complex diseases and, more specifically, identified novel 
asthma-associated gene regions. The first GWAS in 2007 identified several markers on 
chromosome 17q21 specifically associated with nonatopic childhood-onset asthma 
(27). The study examined over 317,000 SNPs in 994 patients and 1,243 controls from 
UK and Germany, and, subsequently the results have been confirmed in Northern 
Europeans, North Americans of European ancestry, Puerto Ricans, Mexicans, Japanese, 
and Chinese, but not in African-Americans (3). Combining gene expression levels with 
the associated SNP genotype a significant asthma association was found with the tran-
scripts of ORMDL3, a transmembrane protein anchored to endoplasmic reticulum, and 
of GSDML, a gasdermin protein regulating apoptosis in epithelial cells. Another GWAS 
included 359 North American of European ancestry asthmatic patients and demon-
strated a significant association between asthma and variants of the PDE4D gene, 
mapped on chromosome 5q12 and coding for a lung-expressed phosphodiesterase 
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involved in airway contractility (28). Ten independent studies attempted to replicate this 
association, but only in Caucasian cohorts a weak association between asthma and two 
out of seven PDE4D SNPs was reported (3). Further, a recent GWAS, together with the 
previously reported association with 17q21 locus, demonstrated a novel asthma locus 
on 1q31 in two independent cohorts of 793 and 917 patients with asthma of North 
American of European ancestry, but not in African ancestry patients (29). The locus 
contains the gene DENND1B which is expressed by natural killer (NK) and dendritic 
cells and is possibly involved in the TNF-a pathway. Interestingly, in the patients of 
African ancestry 17 SNPs at 1q31 locus have been found to be associated with asthma 
but at each SNPs the alternative allele was associated with asthma compared to the 
discovery set. Finally, a GWAS has been conducted on 935 African-American, 929 
African Caribbean, but no significant associations were determined (30).
ePiGeneTics
The incomplete concordance between monozygotic twins and the reported associa-
tions observed in subgroups of patients with asthma clearly suggest that additional fac-
tors are needed to determine disease onset. Accordingly, epigenetics (i.e., DNA 
methylation and/or various post-translational modifications of histones mediated by 
acetyltransferase/deacetylase enzymes) appears as an ideal link between the environ-
ment and genomics and may thus play an important role in the expression of multiple 
inflammatory genes in asthma (31). Moreover, epigenetics seems to explain the corti-
costeroid resistance in patients with COPD.
Gene expression is determined by a balance between histone acetylation which acti-
vates transcription and deacetylation which switches off transcription. An altered 
expression of inflammatory genes and an elevated acetylation of histone-4 were found 
in patients with asthma; moreover, the degree of histone acetylation seems to correlate 
with disease severity (32). It has been observed that in the lung tissue of patients with 
asthma the increased acetylation of histones associated with inflammatory gene hyper-
expression is not secondary to an increase in histone acetyltransferase activity, but due 
to decreased histone deacetylase activity. These mechanisms are particularly interesting 
in consideration of the fact that the anti-inflammatory activity of corticosteroids is 
partly due to epigenetic mechanisms and is directed to suppress NF-kB regulated genes 
including several of the inflammatory genes hyperexpressed in asthma (31). After dif-
fusing across cell membrane, corticosteroids bind their receptor and translocate into the 
nucleus where the receptor has to be acetylated to bind the glucocorticoid receptor rec-
ognition element sited in the promoters of the steroid-sensitive genes. However, it is 
also necessary that the corticosteroid receptor is deacetylated by histone deacetylase 2 
(HDAC2) to inhibit NF-kB. In peripheral blood mononuclear cells and alveolar macro-
phages of patients with asthma and corticosteroid resistance, HDAC2 has been found to 
be markedly reduced (32). Further, the corticosteroid resistance of COPD bronchoal-
veolar macrophages is reversed by overexpression of HDAC2. The mechanisms result-
ing in HDAC2 reduction in COPD are based on the inactivation, ubiquitination, and 
degradation of the enzyme by oxidative and nitric oxide-mediated stress. The formation 
of peroxynitrite, which nitrates tyrosine residues on HDCA2, and the activation of 
PI3k-d by oxidative stress, which leads to phosphorylation of HDCA2, are the main 
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
Un
co
rre
cte
d P
ro
of
Selmi et al.
mechanisms underlying corticosteroid resistance in COPD. In addition, corticosteroids 
switch on corticosteroid-responsive genes, such as MKP-1, via acetylation of K5 and 
K16 on histone-4, and it has been reported, in some asthma patients, that acetylation of 
histone-4 K5 fails to occur. Besides the role of histone acetylation and deacetylation in 
the regulation of inflammatory genes, histone methylation seems also to be involved; 
moreover, corticosteroids seem partially act through this mechanism in inhibiting 
inflammatory genes (33).
Interestingly, it has been proved that theophylline can selective activate HDCA2 in 
macrophages of COPD patients, and ultimately counteract and reverse corticosteroids 
resistance. These data have been reproduced in murine models and in smokers asthma 
patients. Theophylline is effective in accelerating COPD exacerbation recovery and to 
reduce inflammatory mediators. The mechanism of action of theophylline at molecular 
level seems to be via inhibition of PI3k-d (34).
concLusions And fuTure direcTions
This summary of the observed genetic associations in asthma clearly illustrate our 
incomplete understanding of the susceptibility to this complex condition. The mecha-
nisms involved in the genetics of asthma are illustrated in Fig. 1. Similar to other 
multifactorial diseases, GWAS were welcomed as the solution to our knowledge gaps 
but have so far failed to prove conclusive or to report associations that may be used in 
the clinical workup of patients or first-degree relatives of patients. Indeed, reported 
associations include potential candidate genes that fit well within the current patho-
genesis theories. On the other hand, we submit that the upcoming availability and 
accessibility of next-generation sequencing and genome-wide epigenetics tools may 
report additional associations (possibly with rare variants) or complementary mecha-
nisms for transcription regulation. Further, given the potential for interactions between 
the genes found to be asthma-related and environmental toxins known to cause oxidative 
damage to the lungs, future research should be planned to explore gene–environment 
interactions. Large studies with accurate measurement of the environmental exposure 
are needed in order to reach adequate power to detect such interactions. Failure to 
account for environmental exposures might partly explain not only the heterogeneity 
of results across studies, but also the overall negative findings. Strong environmental 
effects on asthma phenotypes could mask modest genetic effects and, more impor-
tantly, gene–environment interactions could make the effects of genes become sub-
stantial only in the presence of oxidative exposures and not detectable at a population 
level. Passive smoking, ambient air pollution and endotoxin or other pathogen-associated 
molecules are good candidates for gene–environment interactions in asthma. Variation 
in exposure to these environmental factors across studies is likely to have happened 
given the diverse geographical setting of the studies included, and gene–environment 
interactions might partly explain the large heterogeneity observed. Moreover, there is 
evidence that antioxidant supplementation can modify these gene–environment inter-
active effects, so that the nutritional status of the study population could represent an 
additional source of heterogeneity. The evaluation of gene–environment interactions 
is problematic due to the lack of power of statistical tests for interactions and the 
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high measurement error present in the assessment of most environmental exposures. 
In fact, despite the strong biological rationale, results from the literature on gene–
environment interactions in asthma remain inconclusive. Standardization of methods 
for environmental exposure assessment and full reporting of the interactions tested 
will allow the pooling of data across studies and to reach adequate power to detect 
interactions.
Similarly, further research should evaluate possible gene–gene interactions. Moreover, 
the contribution of ethnicity, childhood vs. adult asthma, and age at onset should be 
considered. Differences in asthma definition may also have played a role in generating 
the observed heterogeneity. Asthma diagnosed by a physician, self-reported doctor-
diagnosed asthma, and self-reported history of asthma differ in sensitivity and specificity. 
Moreover, asthmatic individuals identified through questionnaire in a population-based 
study may have lower severity than patients recruited at a clinic.
Fig. 1. The functional role of the majority of asthma-associated genes in the pathogenesis of the 
disease.
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